An announcement from Cantargia AB ( (SE:CANTA) ) is now available.
Cantargia AB has announced preclinical data published in Cancer Discovery, highlighting the potential of nadunolimab to counteract tumor-driven systemic immunosuppression. The study, conducted by Professor Douglas Hanahan’s team, shows that blocking IL1RAP can overcome resistance to immune therapy in cervical cancer models, suggesting broader potential for nadunolimab in cancer treatment. Clinical data supports these findings, showing a significant decrease in circulating neutrophils in patients treated with nadunolimab, underscoring its potential to improve immunotherapy outcomes.
More about Cantargia AB
Cantargia AB is a biotechnology company specializing in the development of antibody-based treatments for life-threatening diseases. The company has established a platform centered on the protein IL1RAP, which is involved in various cancer forms and inflammatory diseases. Cantargia’s primary oncology program focuses on the antibody nadunolimab (CAN04), which is being clinically studied in combination with chemotherapy for pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer. The company also has a second development program, CAN10, targeting autoimmune and inflammatory diseases.
YTD Price Performance: -2.61%
Average Trading Volume: 2,500
Technical Sentiment Signal: Buy
Current Market Cap: €36.77M
For detailed information about CANTA stock, go to TipRanks’ Stock Analysis page.